

**Information Sources used to develop Oral Anticoagulants for Non-Valvular Atrial Fibrillation (Adult > 18 years)**

- 1. Heidbuchel H et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J;34:2094-106.
- 2. Amdipharm Mercury Company Limited. Summary of product characteristics - Marevan 5 mg tablets.
- 3. Boehringer Ingelheim. Summary of product characteristics - Pradaxa 150 mg hard capsules. <http://www.medicines.org.uk/emc/>
- 4. Bayer plc. Summary of product characteristics - Xarelto 20 mg film-coated tablets. <http://www.medicines.org.uk/emc/>
- 5. Bristol-Myers Squibb-Pfizer. Summary of product characteristics - Eliquis 5 mg film-coated tablets. <http://www.medicines.org.uk/emc/>
- 6. Daiichi Sankyo UK Limited. Summary of product characteristics - Lixiana 60mg film-coated tablets. <http://www.medicines.org.uk/emc/>
- 7. Personal communication, Daiichi Sankyo UK Ltd.
- 8. FDA. Prescribing information SAVAYSA. [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2015/206316bl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316bl.pdf)
- 9. Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press; February 2015. Accessed 19.02.15 via <http://www.medicinescomplete.com>
- 10. NICE Clinical Guideline. Atrial fibrillation: the management of atrial fibrillation (CG180); June 2014. Accessed 02.08.17 via <http://www.nice.org.uk/guidance/CG180>
- 11. NICE Patient decision aid. Atrial fibrillation: medicines to help reduce your risk of a stroke – what are the options? Accessed 01.08.17 via <http://www.nice.org.uk/guidance/cg180/resources/cg180-atrial-fibrillation-update-patient-decision-aid2>
- 12. UKMi. Common questions and answers on the practical use of oral anticoagulants in non-valvular atrial fibrillation (Version 1.1); December 2014. Accessed 02.08.17 via <http://www.swmit.nhs.uk/pdf+/FAQ/swmitrtdcOACcomparisonDec14-finalVersion1.1.pdf>
- 13. Douxfils J et al. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2014;3:e000515.
- 14. Patel MR et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2010;365:883-91.
- 15. Granger CB et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
- 16. Giugliano RP et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104.
- 17. Clinical Knowledge Summaries. Anticoagulation - oral. Last revised July 2015. <http://cks.nice.org.uk/anticoagulation-oral> .

**Acknowledgements**

All primary and secondary care clinicians within Cambridgeshire and Peterborough that commented on draft versions of this pathway.